TWEAK receptor agonists as anti-angiogenic agents

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S134100, C424S143100, C424S155100

Reexamination Certificate

active

07731963

ABSTRACT:
The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.

REFERENCES:
patent: 4777245 (1988-10-01), Foung et al.
patent: 5073492 (1991-12-01), Chen et al.
patent: 5858991 (1999-01-01), Hellerqvist et al.
patent: 6207642 (2001-03-01), Wiley
patent: 6448042 (2002-09-01), Greene
patent: 6492123 (2002-12-01), Holliger et al.
patent: 6544761 (2003-04-01), Greene et al.
patent: 6608048 (2003-08-01), Tsou et al.
patent: 6727225 (2004-04-01), Wiley
patent: 6824773 (2004-11-01), Wiley
patent: 6943146 (2005-09-01), Jakubowski et al.
patent: 7067475 (2006-06-01), Cerretti et al.
patent: 7074408 (2006-07-01), Fanslow, III et al.
patent: 7087725 (2006-08-01), Browning et al.
patent: 7109298 (2006-09-01), Browning et al.
patent: 7129061 (2006-10-01), Browning et al.
patent: 7208151 (2007-04-01), Browning et al.
patent: 2002/0004041 (2002-01-01), Albert et al.
patent: 2002/0042368 (2002-04-01), Fanslow et al.
patent: 2003/0100074 (2003-05-01), Yu et al.
patent: 2003/0148314 (2003-08-01), Berger et al.
patent: 2003/0162712 (2003-08-01), Cerretti et al.
patent: 2003/0170228 (2003-09-01), Ashkenazi et al.
patent: 2003/0198640 (2003-10-01), Yu et al.
patent: 2003/0211096 (2003-11-01), Ashkenazi et al.
patent: 2003/0211993 (2003-11-01), Jakubowski et al.
patent: 2003/0216546 (2003-11-01), Tykocinski
patent: 2003/0228305 (2003-12-01), Frantz et al.
patent: 2004/0014176 (2004-01-01), Ashkenzai et al.
patent: 2004/0018170 (2004-01-01), Shirwan
patent: 2004/0033495 (2004-02-01), Murray et al.
patent: 2004/0038349 (2004-02-01), Hilbert et al.
patent: 2004/0047854 (2004-03-01), Black et al.
patent: 2004/0076955 (2004-04-01), Mack et al.
patent: 2004/0091473 (2004-05-01), DuBose et al.
patent: 2004/0175744 (2004-09-01), Hu et al.
patent: 2004/0253610 (2004-12-01), Wiley
patent: 2005/0008636 (2005-01-01), Rennert
patent: 2005/0054047 (2005-03-01), Wiley
patent: 2005/0054568 (2005-03-01), Ling et al.
patent: 2005/0181375 (2005-08-01), Aziz et al.
patent: 2005/0208046 (2005-09-01), Kim et al.
patent: 2005/0208500 (2005-09-01), Erlander et al.
patent: 2006/0084143 (2006-04-01), Wiley
patent: 2006/0127397 (2006-06-01), Strittmatter
patent: 2007/0110745 (2007-05-01), Rennert
patent: 2007/0280940 (2007-12-01), Winkles et al.
patent: WO 96/18725 (1996-06-01), None
patent: WO 98/05783 (1998-02-01), None
patent: WO 98/35061 (1998-08-01), None
patent: WO 98/55508 (1998-12-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/19490 (1999-04-01), None
patent: WO 99/59614 (1999-11-01), None
patent: WO 99/61471 (1999-12-01), None
patent: WO 00/37638 (2000-06-01), None
patent: WO 00/42073 (2000-07-01), None
patent: WO 01/45730 (2001-06-01), None
patent: WO 01/53486 (2001-07-01), None
patent: WO 01/85193 (2001-11-01), None
patent: WO 03/086311 (2003-10-01), None
patent: WO 2006047172 (2006-05-01), None
patent: WO 2006096487 (2006-09-01), None
patent: WO 2006125632 (2006-11-01), None
patent: WO 2006130429 (2006-12-01), None
patent: WO 2009/140177 (2009-11-01), None
Schnieder et al. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol. Jun. 1999;29(6):1785-92.
Salloum et al., NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res. Dec. 15, 2000;60(24):6958-63.
Abbas AK et al. (eds), Chapter Fifteen, “Immunity to Microbes”,Cellular and Molecular Immunology, Philadelphia: WB Saunders Co. pp. 302-314 (1991).
Abbas AK et al. (eds), Chapter One, “General Properties of Immune Responses”, Introduction to Immunology,Cellular and Molecular Immunology, Philadelphia: WB Saunders Co. pp. 4-12 (1991).
Ashkenazi and Dixit, “Death Receptors: Signaling and Modulation”,Science, vol. 281, pp. 1305-1308 (1998).
Bach-Elias et al., “Presence of autoantibodies against small nuclear ribonucleoprotein epitopes in Chagas' patients' sera”,Parasitol. Res., vol. 84, pp. 196-799 (1998).
Browning et al, “Characterization of surface lymphotoxin forms”J. Immunol, 154:33-46 (1995).
Cassiano et al., “Molecular Cloning of a Novel Receptor for TWEAK”,Scand. J. Immunol. 51 (Supp. 1) 1-111, 2001.
Chaplin and Fu, “Cytokine regulation of secondary lymphoid organ development”,Current Opinion in Immunology, vol. 10, pp. 288-297 (1998).
Chicheportiche et al. “Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies.”Arthritis Res. 2002;4(2):126-33. Epub Nov. 9, 2001.
Chicheportiche et al., “Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory Pathologies”,Biochem Biophys Res Commun., Dec. 9;279(1):162-5 (2000).
Chicheportiche et al., “TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis.”J Biol Chem., 272(51):32401-10, (Dec. 19, 1997).
Colman PM, “Effects of amino acid sequence changes on antibody-antigen interactions,”Res. Immunol.145(1):33-36 (1994).
Dallman, “Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult”,Current Opinion in Immunology, vol. 7, pp. 632-638 (1995).
De Wit et al., “Preferential Activation of Th2 Cells in Chronic Graft-versus-Host Reaction”,The Journal of Immunology, col. 150 (2), pp. 361-366 (1993).
Desplat-Jégo et al., “TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity,”Journal of Neuroimmunology, 133:116-123 (2002).
Donohue et al., “TWEAK Is an Endothelial Cell Growth and Chemotactic Factor That Also Potentiates FGF-2 and VEGF-A Mitogenic Activity,”Arterioscler. Thromb. Vasc. Biol., 23:594-600 (2003).
Durie et al., “Antibody to the Ligand of CD40, gp39, Blocks the Occurrence of the Acute and Chronic Forms of Graft-vs-Host Disease”,J. Clin. Invest., vol. 94, pp. 1333-1338 (1994).
Feng et al., “The Fn 14 Immediate-Early Response Gene Is Induced During Liver Regeneration and Highly Expressed in Both Human and Murine Hepatocellular Carcinomas,”American Journal of Pathology, 156(4):1253-1261 (Apr. 2000).
Ferrara et al., “The Biology of Vascular Endothelial Growth Factor,”Endocr. Rev., 18(1):4-25 (1997).
Flynn et al., “CD4 T Cell Cytokine Differentiation: The B Cell Activation Molecule, OX40 Ligand, Instructs CD4 T Cells to Express Interleukin 4 and Upregulates Expression of the Chemokine Receptor, Blr-1”,J. Exp. Med., vol. 188, pp. 297-304 (1998).
Grewal and Flavell, “The CD40 Ligand”,Immunol. Res., vol. 16, pp. 59-70 (1997).
Grewal and Flavell, “The Role of CD40 Ligand in Costimulation and T-Cell Activation”,Immunol. Rev., vol. 153, pp. 85-106 (1996).
Hahm et al., “TWEAK overexpression induces hyperplasia in liver and kidney,”FASEB J., Abstract # 471.5, vol. 17, No. 4-5 (Mar. 2003).
Han et al., “Identification of Differentially Expressed Genes in Pancreatic Cancer Cells Using cDNA Microarray,”Cancer Research, 62:2890-2896 (May 15, 2002).
Ho et al., “Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Overexpression in HEK293 Cells Promotes Tumor Growth and Angiogenesis in Athymic Nude Mice,”Cancer Research, 64:8968-8972 (Dec. 15, 2004).
Jakubowski et al., “TWEAK induces liver progenitor cell proliferation,”J. Clin. Invest., 115(9):2330-2340 (Sep. 2005).
Jakubowski, “Dual Role for TWEAK in angiogenic regulation”J. Cell Science, 115:267-274 (2002).
Jakubowski,, “TWEAK Synergizes with Basis Fibroblast Growth Factor to Induce Endothelial Cell Proliferation, Migration and Lumen Morphogenesis”,Scand. J. Immunol., 51:Sup. 1:62 (2000).
Kaduka et al., “TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage,”Biochemical and Biophysical Research Communications, 331

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

TWEAK receptor agonists as anti-angiogenic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with TWEAK receptor agonists as anti-angiogenic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TWEAK receptor agonists as anti-angiogenic agents will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4225991

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.